JOURNAL CLUB ARTICLE PRESENTATION (2)

Dr. Mulinzi Solomon

This article reviews a randomized controlled trial published in Lancet HIV in 2023, examining the virological outcomes of standard-dose dolutegravir (DTG)-based ART in HIV patients also undergoing tuberculosis treatment with rifampicin. It addresses the challenge of rifampicin inducing enzymes that reduce DTG levels, and explores whether standard-dose DTG is sufficient for virological suppression despite potential drug-drug interactions. The review discusses key findings on suppression rates, resistance, and potential policy implications for co-treatment strategies in resource-limited settings.